

Consensus or Controversy? Clinical Investigators Discuss the Optimal Management of Metastatic Renal Cell Carcinoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following results were reported with the combination of pembrolizumab and axitinib in the Phase III KEYNOTE-426 trial, which evaluated the efficacy and safety of pembrolizumab/axitinib versus sunitinib monotherapy as first-line therapy for patients with advanced renal cell carcinoma (RCC)?
 - a. A statistically significant improvement in progression-free survival (PFS) but not overall survival (OS)
 - b. A statistically significant improvement in OS but not PFS
 - c. A statistically significant improvement in PFS and OS
2. In the Phase III METEOR trial evaluating cabozantinib versus everolimus for patients with locally advanced or metastatic clear cell RCC who had received at least 1 anti-VEGFR tyrosine kinase inhibitor, in which of the following subgroups did cabozantinib demonstrate an improvement in both PFS and OS?
 - a. Only patients without bone metastases
 - b. Only patients who had previously received pazopanib
 - c. Only patients who had previously received sunitinib
 - d. Patients with or without bone metastases, regardless of prior therapy
3. The Phase III IMmotion151 trial demonstrated a statistically significant improvement in PFS for patients with previously untreated, PD-L1-positive metastatic RCC with which combination compared to sunitinib?
 - a. Atezolizumab/bevacizumab
 - b. Atezolizumab/lenvatinib
 - c. Pembrolizumab/lenvatinib
 - d. Atezolizumab/tivozanib
 - e. Nivolumab/tivozanib
4. What was reported regarding treatment-free survival (TFS) and toxicity in the Phase III CheckMate 214 trial, which investigated the combination of nivolumab and ipilimumab versus sunitinib monotherapy as first-line therapy for patients with intermediate- or poor-risk advanced RCC?
 - a. Longer TFS without toxicity with sunitinib
 - b. Longer TFS without toxicity with nivolumab/ipilimumab
5. Which of the following combinations is being compared to sunitinib as first-line therapy for patients with advanced RCC in the Phase III CLEAR trial?
 - a. Lenvatinib with everolimus or pembrolizumab
 - b. Lenvatinib with nivolumab or pembrolizumab
 - c. Tivozanib with everolimus or pembrolizumab
 - d. Pazopanib with nivolumab or pembrolizumab